Adaptive Biotechnologies, of Seattle, entered a collaboration with Bristol-Myers Squibb Co., of New York, for the discovery of immunological biomarkers in oncology

Bristol-Myers Squibb Co., of New York, said the FDA approved a supplemental new drug application for the HIV-1 therapy Sustiva (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg

Inc., of Whitehouse Station, N.J., entered into a nonexclusive deal with Bristol-Myers Squibb Co., of New York, to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus infection genotype 1

Bristol-Myers Squibb Co., of New York, will invest $250 million to expand its large-scale biologics manufacturing facility in Devens, Mass., introducing biologics development and clinical trial manufacturing capabilities and adding about 350 employees

Amylin Pharmaceutical Inc., of San Diego, (later acquired by Bristol-Myers Squibb Co. with help from AstraZeneca plc) is the subject of a three-defendant lawsuit along with Merck & Co

Pfizer Inc., of New York, said the European Commission granted conditional marketing authorization for Bosulif (bosutinib) for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors and for whom Gleevec (imatinib, Novartis AG), Tasigna (nilotinib, Novartis AG) and Sprycel (dasatinib, Bristol-Myers Squibb Co.) are not considered appropriate

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., of New York, said the FDA approved Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nanvalvular atrial fibrillation

The Japanese Ministry of Health, Labor, and Welfare approved Eliquis (apixaban) by Bristol-Myers Squibb Co., of Princeton, N.J., and Pfizer Inc., of New York, for prevention of stroke and embolism in patients with nonvalvular atrial fibrillation

Bristol-Myers Squibb Co., of New York, joined the Multiple Myeloma Research Foundation pre-competitive consortium to discover and accelerate new approaches to treating multiple myeloma through the organization's Personalized Medicine Initiative

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the European Commission approved Eliquis (apixaban) for prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation with one or more risk factors

Bristol-Myers Squibb Co., of New York, and AstraZeneca plc, of London, said the European Commission approved Forxiga (dapaglifozin) tablets for Type II diabetes in the European Union

The European Commission approved New York-based Bristol-Myers Squibb Co.'s Baraclude (entecavir) Summary of Product Characteristics update after reviewing new efficacy and safety data in patients with chronic hepatitis B following a liver transplant

Bristol-Myers Squibb Co., of New York, said the National Institute of Health and Clinical Excellence decided to recommend Yervoy (ipilimumab), which is approved in Europe for treating advanced metastatic melanoma, within the final appraisal determination

Bristol-Myers Squibb Co., of New York, said the FDA approved an update to the labeling for Baraclude (entecavir) to include data on African-Americans and liver transplant patients with chronic hepatitis B infection

Bristol-Myers Squibb Co., of New York, said the European Commission granted marketing authorization for the subcutaneous formulation of Orencia (abatacept) in combination with methotrexate for the treatment of adults with moderate to severe active rheumatoid arthritis

Sanofi SA, of Paris, and Bristol-Myers Squibb Co. (BMS), of New York, restructured their long-term alliance following the loss of exclusivity of Plavix (clopidogrel bisulfate) and Avapro (irbesartan)/Avalide (irbesartan-hydrochlorothiazide) in most markets

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA accepted the new drug application resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Bristol-Myers Squibb Co., of New York, and Vanderbilt University said they signed an agreement for the discovery, development and commercialization of therapies acting on the mGluR4 glutamate receptor, or positive allosteric modulators, for the treatment of Parkinson's disease

Life Technologies Corp., of Carlsbad, Calif., entered a master development agreement with Bristol-Myers Squibb Co., of New York, for current and future companion diagnostics projects